Table of Content


Chapter 1   Methodology and Scope
1.1    Market scope and definitions
1.2    Research design
1.2.1    Research approach
1.2.2    Data collection methods
1.3    Base estimates and calculations
1.3.1    Base year calculation
1.3.2    Key trends for market estimation
1.4    Forecast model
1.5    Primary research and validation
1.5.1    Primary sources
1.5.2    Data mining sources
Chapter 2   Executive Summary
2.1    Industry 360? Synopsis
Chapter 3   Industry Insights
3.1    Industry ecosystem analysis
3.2    Industry impact forces
3.2.1    Growth drivers
3.2.1.1    Rising prevalence of chronic diseases
3.2.1.2    Technological advancements in computational modeling
3.2.1.3    Rising demand for personalized medicine
3.2.1.4    Increasing use of AI and machine Learning
3.2.2    Industry pitfalls and challenges
3.2.2.1    High costs of biosimulation software and services
3.2.2.2    Lack of skilled professionals
3.3    Growth potential analysis
3.4    Regulatory landscape
3.5    Technological landscape
3.6    Future market trends
3.7    Porter’s analysis
3.8    PESTEL analysis
Chapter 4   Competitive Landscape, 2024
4.1    Introduction
4.2    Company market share analysis
4.3    Company matrix analysis
4.4    Competitive analysis of major market players
4.5    Competitive positioning matrix
4.6    Strategy dashboard
Chapter 5   Market Estimates and Forecast, By Offering, 2021 – 2034 ($ Mn)
5.1    Key trends
5.2    Software
5.2.1    Integrated software suites/platform
5.2.1.1    Molecular modeling and simulation software
5.2.1.2    Clinical trial design software
5.2.1.3    PK/PD modeling and simulation software
5.2.1.4    Pbpk modeling and simulation software
5.2.1.5    Toxicity prediction software
5.2.1.6    Other integrated software suites/platforms
5.2.2    Standalone modules
5.3    Service
Chapter 6   Market Estimates and Forecast, By Application, 2021 – 2034 ($ Mn)
6.1    Key trends
6.2    Drug discovery
6.3    Drug development
6.4    Disease modeling
6.5    Other applications
Chapter 7   Market Estimates and Forecast, By Therapeutic Area, 2021 – 2034 ($ Mn)
7.1    Key trends
7.2    Oncology
7.3    Cardiovascular disease
7.4    Neurological disorder
7.5    Infectious diseases
7.6    Other therapeutic areas
Chapter 8   Market Estimates and Forecast, By Delivery Model, 2021 – 2034 ($ Mn)
8.1    Key trends
8.2    Subscription models
8.3    Ownership models
8.3.1    License-based model
8.3.2    Pay per use model
8.4    Service based models
Chapter 9   Market Estimates and Forecast, By Deployment Model, 2021 – 2034 ($ Mn)
9.1    Key trends
9.2    On premises model
9.3    Cloud based model
Chapter 10   Market Estimates and Forecast, By End Use, 2021 – 2034 ($ Mn)
10.1    Key trends
10.2    Pharmaceutical and biotechnology companies
10.3    Contract research organizations (CROs)
10.4    Academic research institutions
Chapter 11   Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)
11.1    Key trends
11.2    North America
11.2.1   U.S.
11.2.2   Canada
11.3    Europe
11.3.1   Germany
11.3.2   UK
11.3.3   France
11.3.4   Spain
11.3.5   Italy
11.3.6   Netherlands
11.4    Asia Pacific
11.4.1   China
11.4.2   Japan
11.4.3   India
11.4.4   Australia
11.4.5   South Korea
11.5    Latin America
11.5.1   Brazil
11.5.2   Mexico
11.5.3   Argentina
11.6    Middle East and Africa
11.6.1   South Africa
11.6.2   Saudi Arabia
11.6.3   UAE
Chapter 12   Company Profiles
12.1    Allucent
12.2    Advanced Chemistry Development
12.3    Certara, USA
12.4    Cellworks
12.5    Chemical Computing Group
12.6    Dassault Syst?mes
12.7    Genedata
12.8    In Silico Biosciences
12.9    Immunetrics
12.10    OpenEye
12.11    Physiomics
12.12    Simulations Plus
12.13    Schr?dinger
12.14    Thermo Fisher Scientific
12.15    VeriSIM Life